Clinical study of Dengzhan Shenmai Capsules for Unstable Angina Pectoris
Jia Shuhong
Wang Zhenyu
Wang Yanli
Feng Yaohui
Xie Xiao
Abstract：Objective To observe the clinical efficacy of Dengzhan Shenmai Capsules in the treatment of unstable angina pectoris (UAP). Methods A total of 150 UAP patients admitted to the Department of Health and Welfare of Beijing Chinese Medicine Hospital affiliated to Capital Medical University from October 2015 to August 2018 were enrolled in the study. They were randomly divided into the control group (n=75) and the observation group (n=75). The control group received conventional treatment, and the observation group was given Dengzhan Shengmai capsule (0.18g, 2 capsules/time, 3 times/d) based on conventional treatment, and the treatment was performed for 2 months. After treatment, the clinical efficacy, 24 h myocardial ischemia, duration and total ischemic load were compared. Hemorheology included whole blood viscosity, plasma viscosity, hematocrit, fibrinogen and erythrocyte sedimentation rate; HAMA, HADA, and SF-36 scales were used to assess anxiety, depression, and quality of life, and adverse events were recorded. Results After treatment, the number of myocardial ischemic attacks, duration, total ischemic load, hemorheological parameters (whole blood viscosity, plasma viscosity, hematocrit, fibrinogen, erythrocyte sedimentation rate) and HAMA, HADA were compared between the two groups. Before the decrease, the scores of physiological function, physical pain, overall health, vitality and mental health in the SF-36 scale were higher than those before treatment (P<0.05). Compared with the control group, the observation was compared. The myocardial ischemia duration, total ischemic load, whole blood viscosity, plasma viscosity, erythrocyte sedimentation rate, HAMA, HADA, SF-36 scale showed more significant improvement in physical pain, vitality and mental health (P<0.05). The total effective rate of the observation group was 88.9%, which was significantly higher than that of the control group (69.8%) (P<0.05). No significant adverse reactions occurred in either group. Conclusions Dengzhan Shenmai Capsules is effective and safe for patients with UAP.
Keywords：Dengzhan Shenmai CapsulesUnstable angina pectorisClinical efficacyQuality of life
Publication Date：2019-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 986-988,991 )